On the public citation graph

COVID-19 in patients with multiple sclerosis undergoing disease-modifying treatments

https://doi.org/10.1177/1352458520971817

0 signed · 92 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.

Claim with ORCID

Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.

See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1001/jamaneurol.2020.2581openalex-snapshot

Clinical Characteristics and Outcomes in Patients With Coronavirus Disease 2019 and Multiple Sclerosis

inferredcites →https://doi.org/10.1002/ana.21939openalex-snapshot

Abnormal B‐cell cytokine responses a trigger of T‐cell–mediated disease in MS?

inferredcites →https://doi.org/10.1016/j.cell.2020.04.026openalex-snapshot

Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19

inferredcites →https://doi.org/10.1016/j.cell.2020.05.015openalex-snapshot

Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals

inferredcites →https://doi.org/10.1016/j.chom.2016.01.007openalex-snapshot

Dysregulated Type I Interferon and Inflammatory Monocyte-Macrophage Responses Cause Lethal Pneumonia in SARS-CoV-Infected Mice

inferredcites →https://doi.org/10.1016/j.immuni.2014.02.006openalex-snapshot

Noncanonical NF-κB Pathway Controls the Production of Type I Interferons in Antiviral Innate Immunity

inferredcites →https://doi.org/10.1016/j.jns.2019.01.007openalex-snapshot

Factors associated with dimethyl fumarate-induced lymphopenia

inferredcites →https://doi.org/10.1016/j.msard.2020.102073openalex-snapshot

The COVID-19 pandemic and the use of MS disease-modifying therapies

inferredcites →https://doi.org/10.1016/j.msard.2020.102135openalex-snapshot

Anti-CD20 immunosuppressive disease-modifying therapies and COVID-19

inferredcites →https://doi.org/10.1016/j.msard.2020.102195openalex-snapshot

B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran

inferredcites →https://doi.org/10.1016/j.msard.2020.102315openalex-snapshot

Attenuation of antibody response to SARS-CoV-2 in a patient on ocrelizumab with hypogammaglobulinemia

inferredcites →https://doi.org/10.1016/j.msard.2020.102323openalex-snapshot

Is serological response to SARS-CoV-2 preserved in MS patients on ocrelizumab treatment? A case report

inferredcites →https://doi.org/10.1016/j.msard.2020.102472openalex-snapshot

Evaluation of the rate of COVID-19 infection, hospitalization and death among Iranian patients with multiple sclerosis

inferredcites →https://doi.org/10.1016/s0140-6736(20)30566-3openalex-snapshot

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

inferredcites →https://doi.org/10.1016/s0165-5728(00)00266-6openalex-snapshot

Activation of glial cells by human coronavirus OC43 infection

inferredcites →https://doi.org/10.1016/s1474-4422(20)30147-2openalex-snapshot

An Italian programme for COVID-19 infection in multiple sclerosis

inferredcites →https://doi.org/10.1016/s2666-5247(20)30004-5openalex-snapshot

Comparative tropism, replication kinetics, and cell damage profiling of SARS-CoV-2 and SARS-CoV with implications for clinical manifestations, transmissibility, and laboratory studies of COVID-19: an observational study

inferredcites →https://doi.org/10.1038/s41392-020-0148-4openalex-snapshot

Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study

inferredcites →https://doi.org/10.1038/s41467-020-18764-3openalex-snapshot

SARS-CoV2-mediated suppression of NRF2-signaling reveals potent antiviral and anti-inflammatory activity of 4-octyl-itaconate and dimethyl fumarate

inferredcites →https://doi.org/10.1038/s41577-020-00436-4openalex-snapshot

Not just antibodies: B cells and T cells mediate immunity to COVID-19

inferredcites →https://doi.org/10.1038/s41577-020-0311-8openalex-snapshot

The trinity of COVID-19: immunity, inflammation and intervention

inferredcites →https://doi.org/10.1038/s41586-020-2456-9openalex-snapshot

Convergent antibody responses to SARS-CoV-2 in convalescent individuals

inferredcites →https://doi.org/10.1038/s41591-020-0897-1openalex-snapshot

Antibody responses to SARS-CoV-2 in patients with COVID-19

inferredcites →https://doi.org/10.1038/s41591-020-0965-6openalex-snapshot

Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections

inferredcites →https://doi.org/10.1038/srep25359openalex-snapshot

Comparative and kinetic analysis of viral shedding and immunological responses in MERS patients representing a broad spectrum of disease severity

inferredcites →https://doi.org/10.1056/nejm200503173521125openalex-snapshot

Leflunomide for Polyomavirus Type BK Nephropathy

inferredcites →https://doi.org/10.1056/nejmc2025179openalex-snapshot

Rapid Decay of Anti–SARS-CoV-2 Antibodies in Persons with Mild Covid-19

inferredcites →https://doi.org/10.1056/nejmoa1206328openalex-snapshot

Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis

inferredcites →https://doi.org/10.1084/jem.20111675openalex-snapshot

B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6–producing B cells

inferredcites →https://doi.org/10.1086/500469openalex-snapshot

Two‐Year Prospective Study of the Humoral Immune Response of Patients with Severe Acute Respiratory Syndrome

inferredcites →https://doi.org/10.1093/brain/awq386openalex-snapshot

Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway

inferredcites →https://doi.org/10.1093/ofid/ofy174openalex-snapshot

Infectious Complications of Multiple Sclerosis Therapies: Implications for Screening, Prophylaxis, and Management

inferredcites →https://doi.org/10.1111/cns.13034openalex-snapshot

Immunogenicity and predictors of response to a single dose trivalent seasonal influenza vaccine in multiple sclerosis patients receiving disease‐modifying therapies

inferredcites →https://doi.org/10.1111/j.1365-2249.2004.02415.xopenalex-snapshot

Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome

inferredcites →https://doi.org/10.1111/j.1469-0691.2004.01009.xopenalex-snapshot

Chronological evolution of IgM, IgA, IgG and neutralisation antibodies after infection with SARS-associated coronavirus

inferredcites →https://doi.org/10.1111/joim.12395openalex-snapshot

Human autoimmune diseases: a comprehensive update

inferredcites →https://doi.org/10.1126/science.abd4585openalex-snapshot

Autoantibodies against type I IFNs in patients with life-threatening COVID-19

inferredcites →https://doi.org/10.1128/mbio.01174-14openalex-snapshot

Pathogenic Influenza Viruses and Coronaviruses Utilize Similar and Contrasting Approaches To Control Interferon-Stimulated Gene Responses

inferredcites →https://doi.org/10.1128/mbio.01872-15openalex-snapshot

The Membrane Protein of Severe Acute Respiratory Syndrome Coronavirus Functions as a Novel Cytosolic Pathogen-Associated Molecular Pattern To Promote Beta Interferon Induction via a Toll-Like-Receptor-Related TRAF3-Independent Mechanism

inferredcites →https://doi.org/10.1172/jci137244openalex-snapshot

Clinical and immunological features of severe and moderate coronavirus disease 2019

inferredcites →https://doi.org/10.1212/nxi.0000000000000360openalex-snapshot

Both cladribine and alemtuzumab may effect MS via B-cell depletion

inferredcites →https://doi.org/10.1212/nxi.0000000000000403openalex-snapshot

Teriflunomide treatment reduces B cells in patients with MS

inferredcites →https://doi.org/10.1212/nxi.0000000000000693openalex-snapshot

Impact of treatment on cellular immunophenotype in MS

inferredcites →https://doi.org/10.1212/nxi.0000000000000783openalex-snapshot

COVID-19 in MS

inferredcites →https://doi.org/10.1212/wnl.0000000000001302openalex-snapshot

Randomized trial of vaccination in fingolimod-treated patients with multiple sclerosis

inferredcites →https://doi.org/10.1212/wnl.0000000000008157openalex-snapshot

Practice guideline update summary: Vaccine-preventable infections and immunization in multiple sclerosis

inferredcites →https://doi.org/10.1212/wnl.0000000000010380openalex-snapshot

Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis

inferredcites →https://doi.org/10.1371/journal.ppat.1006286openalex-snapshot

The NF-κB-dependent and -independent transcriptome and chromatin landscapes of human coronavirus 229E-infected cells

inferredcites →https://doi.org/10.21037/atm-20-3307openalex-snapshot

Effectiveness and safety of glucocorticoids to treat COVID-19: a rapid review and meta-analysis

inferredcites →https://doi.org/10.3389/fimmu.2017.00296openalex-snapshot

Sphingosine 1-Phosphate: A Novel Target for Lung Disorders

inferredcites →https://doi.org/10.3389/fimmu.2019.01545openalex-snapshot

A General Introduction to Glucocorticoid Biology

inferredcites →https://doi.org/10.3390/jcm9051450openalex-snapshot

CD56bright Natural Killer Cells: A Possible Biomarker of Different Treatments in Multiple Sclerosis

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.3801769openalex-extracted

Increased Rate of Hospitalisation for COVID-19 Amongst Rituximab Treated Multiple Sclerosis Patients: A Study of the Swedish MS Registry

inferred← citeshttps://doi.org/10.1007/s00115-021-01155-4openalex-snapshot

Die Corona-Pandemie und Multiple Sklerose: Impfungen und deren Implikationen für Patienten – Teil 1: Empfehlungen

inferred← citeshttps://doi.org/10.1007/s00415-022-11003-3openalex-snapshot

Effect of disease-modifying treatments on antibody-mediated response to anti-COVID19 vaccination in people with multiple sclerosis

inferred← citeshttps://doi.org/10.1007/s00415-022-11237-1openalex-snapshot

SARS-CoV-2 infection in multiple sclerosis patients: interaction with treatments, adjuvant therapies, and vaccines against COVID-19

inferred← citeshttps://doi.org/10.1007/s10072-021-05846-3openalex-snapshot

Systematic review of risk of SARS-CoV-2 infection and severity of COVID-19 with therapies approved to treat multiple sclerosis

inferred← citeshttps://doi.org/10.1007/s40120-023-00520-6openalex-snapshot

Cladribine Tablets Mode of Action, Learning from the Pandemic: A Narrative Review

inferred← citeshttps://doi.org/10.1016/b978-3-437-21073-0.00003-9openalex-snapshot

10.1016/b978-3-437-21073-0.00003-9

inferred← citeshttps://doi.org/10.1016/b978-3-437-21073-0.00047-7openalex-snapshot

10.1016/b978-3-437-21073-0.00047-7

inferred← citeshttps://doi.org/10.1016/b978-3-437-21884-2.00003-9openalex-snapshot

Immunmediierte Erkrankungen des Nervensystems

inferred← citeshttps://doi.org/10.1016/b978-3-437-21884-2.00033-7openalex-snapshot

Literaturverzeichnis

inferred← citeshttps://doi.org/10.1016/j.clim.2026.110683openalex-snapshot

Effect of dynamics and timing of SARS-CoV-2 vaccination on immune response in people with multiple sclerosis during cladribine treatment

inferred← citeshttps://doi.org/10.1016/j.jns.2021.117501openalex-snapshot

Personalizing ocrelizumab treatment in Multiple Sclerosis: What can we learn from Sars-Cov2 pandemic?

inferred← citeshttps://doi.org/10.1016/j.msard.2021.102800openalex-snapshot

COVID-19 and disease-modifying therapies in patients with demyelinating diseases of the central nervous system: A systematic review

inferred← citeshttps://doi.org/10.1016/j.msard.2021.102913openalex-snapshot

How the COVID-19 Pandemic has changed multiple sclerosis clinical practice: Results of a nationwide provider survey

inferred← citeshttps://doi.org/10.1016/j.msard.2021.102968openalex-snapshot

The outcome of a national MS-Covid-19 study: What the Turkish MS cohort reveals?

inferred← citeshttps://doi.org/10.1016/j.msard.2021.102984openalex-snapshot

The course of COVID-19 infection in patients with multiple sclerosis–The experience of one center based on the population of Upper Silesia

inferred← citeshttps://doi.org/10.1016/j.msard.2021.103004openalex-snapshot

Registry of patients with multiple sclerosis and COVID-19 infection in Saudi Arabia

inferred← citeshttps://doi.org/10.1016/j.msard.2022.103554openalex-snapshot

Humoral and cellular immune responses to SARS CoV-2 vaccination in People with Multiple Sclerosis and NMOSD patients receiving immunomodulatory treatments

inferred← citeshttps://doi.org/10.1016/j.msard.2022.103893openalex-snapshot

SARS-CoV-2 infection in patients with neuroimmunological disorders in a tertiary referral centre from the north of Portugal

inferred← citeshttps://doi.org/10.1016/j.msard.2022.104156openalex-snapshot

COVID-19 severity among patients with multiple sclerosis treated with cladribine: A systematic review and meta-analysis

inferred← citeshttps://doi.org/10.1016/j.msard.2024.105790openalex-snapshot

Disease-modifying therapies, outcomes, risk factors and severity of COVID-19 in multiple sclerosis: A MENACTRIMS registry based study

inferred← citeshttps://doi.org/10.1016/j.neurol.2022.11.003openalex-snapshot

Serology results after COVID vaccine in multiple sclerosis patients treated with fingolimod

inferred← citeshttps://doi.org/10.1080/1744666x.2022.2064845openalex-snapshot

Impact of immunotherapies on COVID-19 outcomes in multiple sclerosis patients

inferred← citeshttps://doi.org/10.1089/vim.2023.0035openalex-snapshot

Effect of Disease-Modifying Therapies on COVID-19 Vaccination Efficacy in Multiple Sclerosis Patients: A Comprehensive Review

inferred← citeshttps://doi.org/10.1093/cid/ciac404openalex-snapshot

Humoral and T-Cell Immune Response After 3 Doses of Messenger RNA Severe Acute Respiratory Syndrome Coronavirus 2 Vaccines in Fragile Patients: The Italian VAX4FRAIL Study

inferred← citeshttps://doi.org/10.1093/jimmun/vkaf085openalex-snapshot

Interferon-β treatment reverses the detrimental effect of B-cell depletion therapy on respiratory virus infection

inferred← citeshttps://doi.org/10.1139/cjm-2021-0242openalex-snapshot

Interplay between stress and immunity triggers herpes zoster infection in COVID-19 patients: a review

inferred← citeshttps://doi.org/10.1177/13524585211026272openalex-snapshot

Increased rate of hospitalisation for COVID-19 among rituximab-treated multiple sclerosis patients: A study of the Swedish multiple sclerosis registry

inferred← citeshttps://doi.org/10.1177/13524585211069068openalex-snapshot

The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021

inferred← citeshttps://doi.org/10.1177/13524585231151948openalex-snapshot

Characteristics of pediatric patients with multiple sclerosis and related disorders infected with SARS-CoV-2

inferred← citeshttps://doi.org/10.1177/17562864211058298openalex-snapshot

Expert opinion on COVID-19 vaccination and the use of cladribine tablets in clinical practice

inferred← citeshttps://doi.org/10.1186/s41983-021-00287-3openalex-snapshot

Multiple sclerosis patients and COVID-19

inferred← citeshttps://doi.org/10.17116/jnevro202212207296openalex-snapshot

Long-term treatment for multiple sclerosis with interferon beta-1b. Outcomes of an open, retrospective, observational study

inferred← citeshttps://doi.org/10.2174/1570159x20666211217160451openalex-snapshot

Vaccination Opportunities in Multiple Sclerosis Patients Treated with Cladribine Tablets

inferred← citeshttps://doi.org/10.2196/preprints.38023openalex-snapshot

Clinical characteristics, re-infection, seropositivity and the role of Disease Modifying Drugs (DMDs) in COVID-19 infected MS and NMOSD patients: A 12 months follow-up report from Iran (Preprint)

inferred← citeshttps://doi.org/10.2196/preprints.38611openalex-snapshot

Clinical characteristics, re-infection, seropositivity and the role of Disease Modifying Drugs (DMDs) in COVID-19 infected MS and NMOSD patients: A 12 months follow-up report from Iran (Preprint)

inferred← citeshttps://doi.org/10.22379/anc.v39i2.1446openalex-snapshot

COVID-19 en pacientes con esclerosis múltiple: estudio observacional retrospectivo en un centro de referencia colombiano

inferred← citeshttps://doi.org/10.29399/npa.28503openalex-snapshot

Association of mRNA versus inactivated Covid-19 vaccine responses with smoking in Multiple Sclerosis

inferred← citeshttps://doi.org/10.3389/fneur.2022.828616openalex-snapshot

Vaccine Response in Patients With Multiple Sclerosis Receiving Teriflunomide

inferred← citeshttps://doi.org/10.3390/vaccines9070773openalex-snapshot

Multiple Sclerosis, Disease-Modifying Therapies and COVID-19: A Systematic Review on Immune Response and Vaccination Recommendations

Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.